Latest news with #RonBaker
Yahoo
10 hours ago
- Sport
- Yahoo
NCAA says online abuse related to sports betting declined during this year's March Madness
FILE - In this photo taken with a slow shutter speed, Wichita State's Ron Baker runs during practice for the NCAA college basketball tournament, March 20, 2014, in St. Louis. (AP Photo/Charlie Riedel, file) INDIANAPOLIS (AP) — Online abuse related to sports betting decreased during the NCAA's March Madness basketball tournaments compared with the prior year, but people involved in the competition still received more than 3,000 threatening messages, the NCAA said Tuesday. The NCAA hired Signify Group to monitor messages directed at athletes, coaches, game officials, selection committee members and others with official roles in the tournament. Signify used both artificial intelligence and human analysts to confirm the threats and, when necessary, report them to law enforcement. Advertisement Overall, abuse related to sports betting was down 23%, the NCAA said in a news release. The men's March Madness bracket was notable this year for the scarcity of upsets, with all four No. 1 seeds advancing to the Final Four and Florida, a popular pick to win it all, claiming the national title. On the women's side, three top seeds made the national semifinals and No. 2 seed UConn, among the pre-tournament favorites, won the championship. The NCAA's analysis found that overall, abusive statements directed at people involved in the men's tournament increased by 140% — much of it directed at the selection committee and coaches — while abuse related to sports betting was down 36%. Abuse was down 83% on the women's side and betting-related abuse declined 66%. Advertisement One women's player who was targeted online was Chandler Prater of Mississippi State, who was guarding Southern California star JuJu Watkins when she suffered a season-ending knee injury. 'I received all kinds of messages, so many of them hateful and abusive,' Prater said in a statement. 'It was unlike anything I'd ever experienced before.' Signify's AI flagged more than 54,000 posts, and its human analysts confirmed that 3,161 messages were abusive or threatening, the NCAA said. Those messages were reported to social media platforms and occasionally to law enforcement. The reporting led to the removal of abusive posts and restrictions on social media accounts. NCAA President Charlie Baker said he has made curbing online harassment a top priority. Advertisement 'We have been encouraged to record a reduction in sports betting-related abuse and threat at the 2025 event,' Signify CEO Jonathan Hirshler said, 'as this is often the trigger for the most egregious and threatening content we detect.' ___ AP college basketball:
Yahoo
30-05-2025
- Business
- Yahoo
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer
MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") in collaboration with CytoDyn Inc. ("CytoDyn") presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative breast cancer ("mTNBC") treated with leronlimab and PD-L1 immune checkpoint inhibitors ("ICI"). Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, was tested with and without ICIs in n=28 mTNBC patients. Results indicated that leronlimab treatment correlated with increased expression of PD-L1 on circulating tumor associated cells, as measured using the LifeTracDx® blood test from Creatv. The analysis also revealed promising survival observations among patients who experienced a significant increase in PD-L1 expression and subsequently pursued treatment with an ICI. Four year follow-up results were presented at the ESMO Breast Cancer meeting on May 15, 2025 by Dr. Richard Pestell, available here. The LifeTracDx® is a universal cancer blood test that uses both circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, macrophages that engulf tumor cells, as sensitive and accurate markers for real-time monitoring of tumor response in cancer patients. In the trials presented at ESMO, results showed that monitoring the expressions of PD-L1 before and after induction of leronlimab using the LifeTracDx® blood test identified upregulation of PD-L1 expression in 76% of patients after therapy induction. In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years. About Creatv Bio Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and to pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have an array of clinical applications including predicting response to a new therapy in 30 days, providing companion/complementary diagnostics such as PD-L1 using blood samples, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website. Creatv contacts:Daniel Adams,Ron Baker Chief Scientific OfficerChief Business Officer dan@ 732-783-7132 (office)301-785-5185 (mobile) View original content to download multimedia: SOURCE Creatv MicroTech, Inc. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
18-05-2025
- Sport
- Yahoo
Knicks Fan Favorite Has 3 Words After Series Win Over Celtics
After a rocky Game 5, the New York Knicks decimated the Boston Celtics in Game 6 to advance to the Eastern Conference Finals for the first time since 2000. The Knicks benefited from Celtics forward Jayson Tatum's absence, viciously attacking the boards. The Celtics missed Tatum the most there. Advertisement According to the Knicks rebounded 45% of their misses, and the second-chance points really set the two teams apart. May 16, 2025; New York, New York, USA; New York Knicks center Karl-Anthony Towns (32) reacts during the second quarter of game six in the second round of the 2025 NBA Playoffs against the Boston Celtics at Madison Square Garden. Mandatory Credit: Brad Penner-Imagn Images© Brad Penner-Imagn Images Knicks fan favorite has 3 words after win over Celtics Waiting for them in the Eastern Conference Finals is the Indiana Pacers. The Knicks-Pacers rivalry is quite a storied one. Patrick Ewing and Reggie Miller had many battles as part of this rivalry, with countless big-time moments. Following their win over Boston, former fan favorite Ron Baker sent a three-word message. "Knicks in 6" wrote Baker on Ron Baker went undrafted in the 2016 NBA Draft, but was picked up by the Knicks for the summer league and later signed a contract. Advertisement Baker appeared in 92 games for the Knicks before being traded to the Washington Wizards in the 2018-19 season. He started 13 games in his rookie year. Prior to becoming a Knicks fan-favorite, he helped Fred VanVleet lead the Wichita State Shockers to an appearance in the Midwest Regional Semifinal. The Knicks will have their hands full with a Pacers team that made light work of the admittedly injured No. 1-seeded Cleveland Cavaliers. But if the Knicks can keep forcing turnovers and keep attacking the boards at the same rate, a trip to the NBA Finals isn't out of the question.
Yahoo
27-03-2025
- Health
- Yahoo
LifeTracDx® Blood Test to be Performed in Key Colorectal Clinical Trial
MONMOUTH JUNCTION, N.J., March 27, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. (Creatv) will be collaborating with CytoDyn Therapeutics Corporation (CytoDyn) to assess patient response to their drug using the LifeTracDx® blood test. CytoDyn has received FDA clearance to initiate a Phase II study of leronlimab in patients with relapsed or refractory micro-satellite stable colorectal cancer (CRC) (NCT06699835). The drug, leronlimab, targets CCR5 marker on the tumor. Creatv will perform the LifeTracDx® liquid biopsy in a number of CytoDyn studies including NCT06699835. The LifeTracDx® test is based on analyzing two biomarkers: (1) circulating tumor cells (CTCs) and (2) Cancer Associated Macrophage-Like (CAML) cells, which are macrophages that engulf tumor cells. Both CTCs and CAMLs contain tumor material. By tracking CTC and CAML counts, and CAML size at various time points, LifeTracDx® can provide prognostic insights and predict treatment response. CytoDyn is also interested in the expressions of CCR5 and PD-L1 markers on the tumor. These markers can change over time. LifeTracDx® can provide this information by a blood test - no tissue is required. The LifeTracDx® assay will help CytoDyn to better evaluate the effectiveness of their drug. About Creatv Bio Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have many applications including predicting response to a new therapy in just 30 days, providing companion diagnostics such as PD-L1 and drug targets using blood instead of tissue, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website at For more information contact:Daniel Adams,Ron Baker Chief Scientific OfficerChief Business Officerdan@ (office)301-785-5185 (mobile) View original content to download multimedia: SOURCE Creatv MicroTech, Inc. Sign in to access your portfolio
